MCL1 and breast carcinoma: As an initial indication of potential predictive utility of the PRIMAB readouts, we showed a distinct staining in xenografted human breast cancer cells that are responsive to MCL-1 inhibitor, AZD5591, or not responsive to that treatment (Figure 8C).